Table 1 Study Demographics
Placebo n = 4 | Total NRPT n = 20 | NRPT Dose | ||||
|---|---|---|---|---|---|---|
250/50 mg n = 5 | 500/100 mg n = 5 | 750/150 mg n = 5 | 1000/200 mg n = 5 | |||
Age (years) | ||||||
Mean ± SD | 74.0 ± 4.3 | 68.3 ± 12.8 | 67.9 ± 7.2 | 70.4 ± 8.2 | 62.2 ± 17.3 | 73.9 ± 6.7 |
Sex, n (%) | ||||||
Male | 1 (25) | 16 (80) | 5 (100) | 3 (60) | 4 (80) | 4 (80) |
Race, n (%) | ||||||
White | 4 (100) | 17 (85) | 4 (80) | 4 (80) | 4 (80) | 5 (100) |
African American | 0 | 1 (5) | 0 | 1 (20) | 0 | 0 |
Asian | 0 | 2 (10) | 1 (20) | 0 | 1 (20) | 0 |
Other | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline kidney function, Mean ± SD | ||||||
Cr (mg/dl) | 1.29 ± 0.25 | 1.30 ± 0.29 | 1.37 ± 0.28 | 1.27 ± 0.16 | 1.29 ± 0.47 | 1.26 ± 0.26 |
eGFR (ml/min/1.73m2) | 47.0 ± 15.4 | 56.7 ± 14.6 | 52.4 ± 10.5 | 54.0 ± 12.9 | 60.0 ± 19.3 | 58.6 ± 15.9 |
BUN (mg/dl) | 49.5 ± 23.0 | 26.45 ± 11.25 | 31.2 ± 16.5 | 23.6 ± 5.9 | 20.8 ± 9.3 | 30.2 ± 13.3 |
Cause of AKI, n (%) | ||||||
Drug induced | 2 (50) | 8 (40) | 2 (40) | 1 (20) | 2 (40) | 3 (60) |
Cardiorenal | 2 (50) | 7 (35) | 2 (40) | 2 (40) | 2 (40) | 1 (20) |
Contrast | 3 (15) | 1 (20) | 2 (40) | |||
Hypotension | 2 (10) | 1 (20) | 1 (20) | |||
Characteristics of AKI prior to intervention, Mean ± SD | ||||||
Days of AKI | 2.0 ± 0.8 | 1.8 ± 0.7 | 1.6 ± 0.5 | 2.0 ± 0.7 | 1.6 ± 0.5 | 2.0 ± 1.0 |
AKIN stage (n) | 1 (4) | 1 (19), 2 (1) | 1 (5) | 1 (4), 2 (1) | 1 (5) | 1 (5) |
UOP (L/day) | 1.66 ± 0.91 | 1.74 ± 0.90 | 2.00 ± 1.39 | 1.35 ± 0.80 | 1.67 ± 0.42 | 1.94 ± 0.90 |